FDA Inspection
AstraZeneca Pharmaceuticals LPAstraZeneca Pharmaceuticals LP – FDA Inspection, Oct 25, 2024
Record Details
This FDA Inspection record concerns AstraZeneca Pharmaceuticals LP, with an inspection on October 25, 2024, issued by the Baltimore District Office, covering human drugs.
View Company Profile
ID · da96b405-5d6f-462e-8164-cc589345ae2e
Inspection Facts
- Inspection number
- 1254239
- FDA center
- Human Drugs
Other FDA inspections of AstraZeneca Pharmaceuticals LP
15| Date | Classification | Office | Project area |
|---|---|---|---|
| January 14, 2026 | Not classified | Baltimore District Office | |
| May 31, 2024 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 22, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| July 18, 2023 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| September 30, 2021 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for AstraZeneca Pharmaceuticals LP
- FDA Inspection 1299436 - 2026-01-14
- FDA Inspection 1238346 - 2024-05-31
- FDA Inspection 1230136 - 2024-01-22
- FDA Inspection 1211604 - 2023-07-18
- FDA Inspection 1157291 - 2021-09-30
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.